Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery (l ...

The investment will boost its core capabilities, support upgrades to existing facilities Read more at The Business Times.

Rubber modified asphalt has emerged as one of the most promising avenues for end-of-life tires, but there remains a lot of ...

Education in general, and lifelong learning in particular, are of major strategic importance to the Kingdom of Morocco. His ...